"Receptor, ErbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.
| Descriptor ID |
D018719
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009.400 D12.776.543.750.630.009.400 D12.776.543.750.750.400.074.400 D12.776.624.664.700.642 D23.050.301.500.600.700 D23.050.705.552.600.550 D23.101.140.642
|
| Concept/Terms |
Receptor, ErbB-2- Receptor, ErbB-2
- ErbB-2 Receptor
- Antigens, CD340
- CD340 Antigens
- Proto-Oncogene Proteins c-erbB-2
- Proto Oncogene Proteins c erbB 2
- p185(c-neu)
- c-erbB-2 Protein
- c erbB 2 Protein
- erbB-2 Proto-Oncogene Protein
- Proto-Oncogene Protein, erbB-2
- erbB 2 Proto Oncogene Protein
- erbB-2 Receptor Protein-Tyrosine Kinase
- erbB 2 Receptor Protein Tyrosine Kinase
- neu Proto-Oncogene Protein
- Proto-Oncogene Protein, neu
- neu Proto Oncogene Protein
- HER-2 Proto-Oncogene Protein
- HER 2 Proto Oncogene Protein
- Proto-Oncogene Protein, HER-2
- Proto-Oncogene Protein HER-2
- Proto Oncogene Protein HER 2
- Receptors, erbB-2
- erbB-2 Receptors
- Neu Receptor
- Receptor, Neu
- Metastatic Lymph Node Gene 19 Protein
- Proto-oncogene Protein Neu
- Neu, Proto-oncogene Protein
- Proto-oncogene c-ErbB-2
- c-ErbB-2, Proto-oncogene
- Tyrosine Kinase-type Cell Surface Receptor HER2
- Tyrosine Kinase type Cell Surface Receptor HER2
- p185erbB2 Protein
- CD340 Antigen
- Oncogene Protein HER-2
- Oncogene Protein HER 2
- Proto-Oncogene Protein p185(neu)
|
Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-2".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Transferases [D08.811.913]
- Phosphotransferases [D08.811.913.696]
- Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
- Protein Kinases [D08.811.913.696.620.682]
- Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
- Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
- ErbB Receptors [D08.811.913.696.620.682.725.400.009]
- Receptor, ErbB-2 [D08.811.913.696.620.682.725.400.009.400]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Membrane Proteins [D12.776.543]
- Receptors, Cell Surface [D12.776.543.750]
- Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
- ErbB Receptors [D12.776.543.750.630.009]
- Receptor, ErbB-2 [D12.776.543.750.630.009.400]
- Receptors, Peptide [D12.776.543.750.750]
- Receptors, Growth Factor [D12.776.543.750.750.400]
- ErbB Receptors [D12.776.543.750.750.400.074]
- Receptor, ErbB-2 [D12.776.543.750.750.400.074.400]
- Neoplasm Proteins [D12.776.624]
- Oncogene Proteins [D12.776.624.664]
- Proto-Oncogene Proteins [D12.776.624.664.700]
- Receptor, ErbB-2 [D12.776.624.664.700.642]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Histocompatibility Antigens [D23.050.301.500]
- Minor Histocompatibility Antigens [D23.050.301.500.600]
- Receptor, ErbB-2 [D23.050.301.500.600.700]
- Isoantigens [D23.050.705]
- Histocompatibility Antigens [D23.050.705.552]
- Minor Histocompatibility Antigens [D23.050.705.552.600]
- Receptor, ErbB-2 [D23.050.705.552.600.550]
- Biomarkers [D23.101]
- Biomarkers, Tumor [D23.101.140]
- Receptor, ErbB-2 [D23.101.140.642]
Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-2".
This graph shows the total number of publications written about "Receptor, ErbB-2" by people in this website by year, and whether "Receptor, ErbB-2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 0 | 3 |
| 2004 | 3 | 1 | 4 |
| 2005 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 2 | 2 |
| 2013 | 0 | 1 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 1 | 1 | 2 |
| 2018 | 3 | 1 | 4 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2022 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Receptor, ErbB-2" by people in Profiles.
-
Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results. Clin Cancer Res. 2022 04 01; 28(7):1323-1334.
-
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature. JCO Precis Oncol. 2022 04; 6:e2100463.
-
HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome. Breast Cancer Res Treat. 2022 Jun; 193(2):523-533.
-
Evaluating the Response of Palbociclib on Progression-Free Survival in Hormone Receptor-Positive Metastatic Breast Cancer. Oncology. 2022; 100(6):337-343.
-
Targeting HER2 expression in cancer: New drugs and new indications. Bosn J Basic Med Sci. 2021 Feb 01; 21(1):1-4.
-
Transient commensal clonal interactions can drive tumor metastasis. Nat Commun. 2020 11 16; 11(1):5799.
-
Trastuzumab with carboplatin/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: A cost-effectiveness analysis. Gynecol Oncol. 2021 01; 160(1):214-218.
-
Peritoneal Spread of Ovarian Cancer Harbors Therapeutic Vulnerabilities Regulated by FOXM1 and EGFR/ERBB2 Signaling. Cancer Res. 2020 12 15; 80(24):5554-5568.
-
Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review. Appl Immunohistochem Mol Morphol. 2020 10; 28(9):655-660.
-
Safety and efficacy of T-DM1 in patients with advanced HER2-positive breast cancer The Royal Marsden experience. Cancer Treat Res Commun. 2020; 24:100188.